Powel H. Brown, M.D., Ph.D. - Publications

Selected publications:

Shen Q, Uray IP, Li Y, Zhang Y, Hill J, Xu XC, Young MR, Gunther EJ, Hilsenbeck SG, Colburn NH, Chodosh LA, Brown PH. Targeting the Activator protein 1 transcription factor for the prevention of estrogen receptor-negative mammary tumors. Cancer Prevention Research, 2008. (in press) [PDF]

Li Y, Zhang Y, Hill J, Kim HT, Shen Q, Bissonnette RP, Lamph WW, Brown PH. The rexinoid, bexarotene, prevents the development of premalignant lesions in MMTV-erbB2 mice. Br J Cancer. 2008 Mar 25; [Epub ahead of print] [PDF]

Shen Q, Uray IP, Li Y, Krisko TI, Strecker TE, Kim HT, Brown PH. The AP-1 transcription factor regulates breast cancer cell growth via cyclins and E2F factors. Oncogene. 27(3):366-77, 2008. [PDF]

Li Y, Zhang Y, Hill J, Shen Q, Kim HT, Xu X, Hilsenbeck SG, Bissonnette R, Lamph WW, Brown PH. The rexinoid, LG100268, prevents the development of pre-invasive and invasive ER-negative tumors in MMTV-erbB2 mice. Clinical Cancer Research. 13(20):6224-31, 2007. [PDF]

Duan L, Sterba K, Kolomeichuk S, Kim H, Brown PH, Chambers TC. Inducible overexpression of c-Jun in MCF7 cells causes resistance to vinblastine via inhibition of drug-induced apoptosis and senescence at a step subsequent to mitotic arrest. Biochem Pharmacol. 73(4): 481-90, 2007. [PDF]

Rajkumar L, Kittrell FS, Guzman RC, Brown PH, Nandi S, Medina D. Hormone-induced protection of mammary tumorigenesis in genetically engineered mouse models. Breast Cancer Res. 9(1):R12, 2007. [PDF]

Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, Rasmussen KE, Jones LP, Assefnia S, Chandrasekharan S, Backlund MG, Yin Y, Khramtsov AI, Bastein R, Quackenbush J, Glazer RI, Brown PH, Green JE, Kopelovich L, Furth PA, Palazzo JP, Olopade OI, Bernard PS, Churchill GA, Van Dyke T, Perou CM. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol. 8(5):R76, 2007. [ PDF]

DeNardo DG, Cuba VL, Kim H, Wu K, Lee AV, Brown PH. Estrogen receptor DNA binding is not required for estrogen-induced breast cell growth. Mol Cell Endocrinol. 277(1-2):13-25, 2007. [PDF]

Duan L, Sterba K, Kolomeichuk S, Kim H, Brown PH, Chambers TC. Inducible overexpression of c-Jun in MCF7 cells causes resistance to vinblastine via inhibition of drug-induced apoptosis and senescence at a step subsequent to mitotic arrest. Biochem Pharmacol. 73:481-90, 2007. [PDF]

Li Y, Brown PH. Translational approaches for the prevention of ER-negative breast cancer. Eur J Cancer Prevention. 16:203-215, 2007. [PDF]

Xia D, srinivas H, Ahn YH, Sethi G, Sheng X, Yung WK, Xia Q, Chiao PJ, Kim H, Brown PH, Wistuba II, Aggarwal B, Kurie JM. Mitogen-activated protein kinase kinase-4 promotes cell survival by decreasing PTEN expression through an NFkB-dependent pathway. J Biol Chem. 282:3507-19, 2007. [PDF]

Kim HT, Kong G, DeNardo D, Li Y, Uray I, Pal S, Mohsin S, Hilsenbeck SG, Bissonnette R, Lamph WW, Johnson K, Brown PH. Identification of biomarkers modulated by the RXR-Selective retinoid, LGD1069, in human breast cells using oligonucleotide arrays. Cancer Research 66:12009-12018, 2006. [PDF]

Liby K, Rendi M, Suh N, Royce DB, Risingsong R, Williams CR, Lamph W, Labrie F, Krajewski S, Xu X, Kim HT, Brown P, Sporn MB. The combination of the rexinoid, LG100268, and a SERM, either Arzoxifene or Acolbifene, synergize in the prevention and treatment of mammary tumors in an estrogen receptor negative model of breast cancer. Clinical Cancer Research, 12:5902-9, 2006. [PDF]

Jang K-S, Han H, Paik S, Brown PH, Kong G. Id-1 overexpression in invasive ductal carcinoma cells is significantly associated with intratumoral microvessel density in ER-negative/node-positive breast cancer. Cancer Letters, 244:203-10, 2006. [PDF]

Cui X, Kim H-J, Kuiatse I, Kim HT, Brown PH, Lee AV. Epidermal growth factor induces insulin receptor substrate-2 in breast cancer cells via JNK/AP-1 signaling to regulate cell migration. Cancer Research, 66:5304-13, 2006. [PDF]

Shen Q, Zhang Y, Uray IP, Hill LJ, Kim HT, Lu C, Young MR, Gunther EJ, Hilsenbeck SG, Chodosh LA, Colburn NH, Brown PH. The AP-1 transcription factor regulates postnatal mammary gland development. Developmental Biology, 295:589-603, 2006. [PDF]

Srinivas H, Xia D, Moore NL, Uray IP, Kim H, Ma L, Weigel NL, Brown PH, Kurie JM. Akt phosphorylates and suppresses the transactivation of retinoic acid receptor alpha. Biochem J, 395:653-62, 2006. [PDF]

Wu K, DuPre E, Kim H, Tin-U CK, Bissonnette RP, Lamph WW and Brown PH. Receptor-selective retinoids inhibit the growth of normal and malignant breast cells by inducing G1 cell cycle blockade. Breast Cancer Research and Treatment,96:147-57, 2006. [PDF]

Shen Q, Brown P. Transgenic mouse models for the prevention of breast cancer. Mutation Research 576:93-110, 2005. [PDF]

Lu C, Shen Q, Kim H, Hilsenbeck S, Brown P. cFos is critical for MCF 7 breast cancer cell growth. Oncogene, 24:6516-6524, 2005. [PDF]

Medina D, Kittrell FS, Hill J, Shepard A, Brown P. Tamoxifen inhibition of estrogen receptor-negative mammary tumorigenesis. Submitted to Cancer Research 65:3493-3496, 2005. [PDF]

Kong G, Kim H-T, Wu K, DeNardo D, Hilsenbeck SG, Xu X-C, Lamph WW, Bissonnette R, Dannenberg AJ, and Brown PH. The RXR-selective retinoid, LGD1069, down-regulates COX-2 expression in human breast cells through transcription factor crosstalk: implications for molecular-based chemoprevention. Cancer Research 65:3562-3469, 2005. [PDF]

Denardo DG, Kim HT, Hilsenbeck S, Cuba V, Tsimelzon A, Brown PH. Global gene expression analysis of ER transcription factor cross-talk in breast cancer: Identification of estrogen-induced/AP-1-dependent genes. Molecular Endocrinology, 19:362-378, 2005. [PDF]

Lui Y, Lu C, Shen Q, Munoz-Medellin D, Kim H, Brown PH. AP-1 blockade in breast cancer cells causes cell cycle arrest by suppressing G1 cyclin expression and reducing cyclin dependent kinase activity. Oncogene 23:8238-46, 2004. [PDF]

Lu, C, Mohsin S, Hilsenbeck, S., Wakeling A, Brown PH. Re: Effect of Epidermal Growth Factor Receptor Inhibitor on Development of Estrogen Receptor-Negative Mammary Tumors. J Natl Cancer Inst 96:715-717, 2004.

Lu C, Speers C, Zhang Y, Xu X, Hill J, Steinbis E, Celestino J, Shen Q, Kim H, Hilsenbeck S, Mohsin SK, Wakeling A, Osborne CK, Brown PH. Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. J Natl Cancer Inst 95:1825-1833, 2003. [PDF]

Wu K, Zhang Y, Xu, X-C, Hill J, Celestino J, Kim H-T, Mohsin SK, Hilsenbeck SG, Lamph WW, Bissonette R, and Brown PH. The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice. Cancer Research 62:6376-6380, 2002. [PDF]

Liu Y, Ludes-Meyers J, Zhang Y, Munoz-Medellin D, Kim H-T, Lu C, Ge G, Schiff R, Hilsenbeck SG, Osborne CK, and Brown PH. Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth. Oncogene 21:7680-7689, 2002. [PDF]

Wu K, Kim H-T, Rodriquez JL, Hilsenbeck SG, Mohsin SK, Xu X-C, Lamph WW, Kuhn JG, Green JE, and Brown PH. Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD 1069. Cancer Epidemiology Biomarkers and Prevention 11:467-474, 2002. [PDF]

Ludes-Meyers J, Liu Y, Munoz-Medellin D, Hilsenbeck S, and Brown P. AP-1 blockade inhibits the growth of normal and malignant breast cells. Oncogene 20:2771-2780, 2001. [PDF]
Publications, Books/Chapters

Books/Chapters:

Brown PH, Fuqua S and Allred C. Pathogenesis of Estrogen receptor positive and negative breast cancer. Contemporary Endocrinology: Endocrine Oncology, S. P. Ethier, ed. Humana Press Inc., Totowa, NJ, 49-68, 2000.

Fuqua S, Powel PH, Li Y. Strategies of Hormonal Prevention: Hormone Receptors in Cancer, ed. Springer Science+Business Media Inc., New York, NY.

Publications, Books/Chapters

Research questions? Contact Dr. Brown by email.